Pomerantz Files Class Action Against ARS Pharmaceuticals Over SPRY Losses

A class action lawsuit has been filed against ARS Pharmaceuticals, Inc., the NASDAQ-listed drugmaker trading under the ticker SPRY, New York-based Pomerantz LLP announced on Sept. 24, 2026. The firm is alerting investors who sustained losses on their ARS holdings to take note of approaching case deadlines.

Pomerantz, which specializes in securities litigation, is directing affected shareholders to contact attorney Danielle Peyton at newaction@pomlaw.com or by phone at 646-581-9980. The firm did not disclose in its announcement the specific allegations underlying the complaint or the precise loss threshold required to participate in the class.

Read more Aberdeen Intermediate Income Fund Plans 1-for-6 Reverse Split →

Class action securities lawsuits typically allege that a company or its executives misled investors through materially false or misleading statements, causing share prices to be artificially inflated before declining and generating investor losses. Shareholders who purchased shares during a defined class period may be eligible to seek recovery without paying out-of-pocket legal fees, as plaintiff attorneys in such cases are generally compensated through any eventual settlement or judgment.

Investors considering participation are advised to act promptly, as securities class actions carry court-imposed lead-plaintiff deadlines — typically 60 days from the initial filing announcement — after which the ability to seek appointment as lead plaintiff may be forfeited. Missing the deadline does not necessarily bar recovery as a class member, but it limits an investor's role in directing the litigation.

Continue reading at All Financial Services & Investing.